This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Andreozzi, G. M. Articles by Palazzini, E. Search for Related Content PubMed PubMed Citation Articles by Andreozzi, G. M. Articles by Palazzini, E. Social Bookmarking                   What's this?

Tolerability and Clinical Efficacy of Desmin in the Treatment of Superficial Thrombovaricophlebitis

Chair of Angiology, Department of Internal Medicine, "A. Francaviglia," University of Catania

Salvatore Signorelli

Chair of Angiology, Department of Internal Medicine, "A. Francaviglia," University of Catania

Luigi Di Pino

Chair of Angiology, Department of Internal Medicine, "A. Francaviglia," University of Catania

Romeo Martini

Chair of Angiology, Department of Internal Medicine, "A. Francaviglia," University of Catania

Elsa Marchitelli

Department of Angiology, S. Eugenio Hospital, Rome

Antonio Pinto

Chair of Medical Pathophysiology, University of Catania

Salvatore Romeo

Chair of Vascular Surgery, Department of Vascular Surgery, Garibaldi Hospital, University of Catania

Villiam Zamboni

Medical Department, Alfa Wassermann S.p.A., Bologna, Italy

Ernesto Palazzini

Medical Department, Alfa Wassermann S.p.A., Bologna, Italy

Fifty-six patients with superficial thrombovaricophlebitis of the lower limbs were enrolled in an open and multicenter (4 centers) trial for a period of thirty days. Patients were randomly allocated to three treatment groups to receive a new low-molecular-weight dermatan sulfate (Desmin) at the dose, respectively, of 100 mg once daily by subcuta neous (SC) route, 100 mg twice a day SC, and 200 mg once daily by intramuscular (IM) route. The general and local tolerability and the clinical efficacy of the drug were evaluated by means of clinical, instrumental, and laboratory parameters. Desmin proved capable of effectively improving the symptoms of patients affected by thrombovari cophlebitis, inducing rapid regression by the tenth day of treatment. The daily dose of 200 mg (either SC or IM) was more effective than the 100 mg dose. The systemic toler ability of the drug, administered for the first time for one month, was extremely good, without significant variations in the relevant laboratory tests. Local tolerance (at the site of injection) of the drug was also good.

Angiology, Vol. 47, No. 9, 887-894 (1996)
DOI: 10.1177/000331979604700907


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?